Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be launched as ...
The epidemiology of tumor lysis syndrome is evolving with the introduction of newer therapies. The occurrence of tumor lysis syndrome has become a less predictable but increasingly important aspect of ...
Wendtner has served on advisory boards for AbbVie, Amgen, Astrazeneca, BeOne Medicines, BIONTech, Cllag-Janssen, F. Hoffmann-La Roche, Genentech, Gilead, GSK ...
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic ...
David is comprehensively experienced in many facets of financial and legal research and publishing. As an Investopedia fact checker since 2020, he has validated over 1,100 articles on a wide range of ...
The treatment of CLL has evolved from traditional chemoimmunotherapy (CIT) to an increasing number of targeted and biologic approaches. Randomized trials have demonstrated superiority of covalent ...
This article is part of the TechXchange: Cybersecurity. This article series is in the Communication topic within our Series Library. Designed to be a study guide for a product development engineer, ...
Addressing avoidable emergency department (ED) utilization takes interventions in partnership with providers. Emergency department (ED) utilization contributes significantly to medical expenditure in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results